Abstract: Type II cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG II) is a membrane-anchored enzyme expressed mainly in the intestinal mucosa and the brain, and is associated with various physiological or pathological processes. Upregulation of PKG II is known to induce apoptosis and inhibit proliferation and metastasis of cancer cells. The inhibitory effect of PKG II has been shown to be dependent on the inhibition of the activation of epidermal growth factor receptor (EGFR) and blockade of EGFR downstream signal transduction in vitro. However, it remains unclear whether similar phenomena/mechanisms exist in vivo and whether these effects are independent of cGMP or cGMP analogues. In the present work, nude mice with transplanted orthotopic tumours were infected with adenovirus encoding cDNA of constitutively active PKG II mutant (Ad-a-PKG II) and the effect of constitutively active PKG II (a-PKG II) on tumour development was detected. The results showed that a-PKG II effectively ameliorated gastric tumour development through delaying the growth, inducing the apoptosis, and inhibiting the metastasis and angiogenesis. The effect was related to blockade of EGFR activation and abrogation of the downstream signalling cascades. These findings provide novel insight which will benefit the development of new cancer therapies.
Introduction
Mammalian cyclic guanosine monophosphate (cGMP)-dependent protein kinases (PKGs) are serine/threonine kinases that play critical roles in signal transduction of cGMP-linked hormones and neurotransmitters, such as nitric oxide, natriuretic peptides, guanylin, and some bacterial toxins, through autophosphorylation/activation. 1, 2 Two types of PKGs, PKG I and PKG II, have been identified in mammalian tissues. PKG I, which includes α and β isoforms, is a major mediator of cGMP signalling in mammals and is ubiquitously expressed, especially in smooth muscle, platelets, cerebellum, hippocampus, dorsal root ganglia, neuromuscular junction end plates, and kidney. 3 Numerous studies have indicated that PKG I is involved in diverse pathological and physiological processes, such as cardiovascular homeostasis, various brain functions, excessive food intake response, atherosclerosis, and pathological vessel growth, 2, 4, 5 and it has antiproliferative/pro-apoptotic effects in colon cancer cells and breast cancer. 6, 7 Conversely, PKG II is more tissue specific and is
The constitutively active PKG II mutant effectively inhibits gastric cancer development via a blockade of EGF/EGFRassociated signalling cascades expressed mainly in the brush border of the intestinal mucosa and in various areas of the brain. 5 PKG II is a membrane-anchored kinase that includes a cGMP-binding domain and a catalytic domain in the C terminus. 8 A few functions of PKG II have been demonstrated, 9 and recent evidence indicates that PKG II is involved in various physiological processes, including intestinal fluid homeostasis, skeletal growth, renin secretion, and renal Ca 2+ reabsorption. 5 Furthermore, PKG II-deficient mice exhibited dwarfism caused by a severe defect in endochondral ossification at the growth plates. 10 Additionally, PKG II promoted chondrocyte hypertrophy and skeletal growth by inhibiting the transcription factor SOX9 and by phosphorylation and inactivation of Glycogen synthase kinase 3 beta (GSK-3β). 11, 12 Our group has also reported novel effects of PKG II in cancer cells; specifically, upregulation of PKG II in cancer cell lines by applying the PKG II adenoviral vector (Ad-PKG II), which inhibited cancer cell proliferation and metastasis, and induced apoptosis. The inhibitory effects of PKG II were dependent on abrogation of epidermal growth factor (EGF) or hepatocyte growth factor (HGF)-induced signal transductions in gastric cancer cell lines and other cell lines, including mitogen-activated protein kinase (MAPK), JAK/Stat, phospholipase C-γ (PLCγ) and PI3K/Akt/mTOR cascades. [13] [14] [15] However, the inhibitory effects of PKG II in cancers were demonstrated in vitro, and whether there are similar phenomena in vivo remains unclear. Furthermore, PKG II function depends on activation by cGMP or cGMP analogues, and whether it has biological functions independent of cGMP or cGMP analogues is also unknown. In the present work, we replaced the autophosphorylated residue Ser126 of PKG II with Glu to generate a constitutively active PKG II mutant (a-PKG II) and demonstrated that the mutant can phosphorylate vasodilator-stimulated phosphoprotein (VASP) independent of cGMP or cGMP analogues. We also detected the effects of a-PKG II and wild-type PKG II (wt-PKG II) on the growth of transplanted tumour, the angiogenesis, the metastasis and the apoptosis, as well as the involvement of EGF-receptor (EGFR) activity and its downstream signalling effects. These results provide valuable information that will benefit the development of novel tumour biotherapies.
Materials and methods

Mice and cell lines
Male nude BALB/c mice (6 weeks old) were purchased from the Animal Center of Yangzhou University (Yangzhou City, Jiangsu Province, China) and maintained in the Animal Center of Jiangsu University in compliance with the Guide for the Care and Use of Laboratory Animals (National Research Council [US] Committee). 16 The experimental protocol was approved by the Jiangsu University ethics committee. The human gastric cancer cell line BGC-823 was obtained from the Institute of Cell Biology (Shanghai, China) and cultured in DMEM supplemented with 10% fetal bovine serum (FBS) in a humidified atmosphere of 5% CO 2 at 37°C.
Reagents
Adenoviral vectors encoding cDNA of green fluorescent protein (Ad-GFP) and PKG II (Ad-wt-PKG II) were constructed following our lab protocol. DMEM and FBS were obtained from Gibco (Grand Island, NY, USA). The primary antibodies against PCNA, Bcl-2, Bax, Caspase 3, E-cadherin, MMP-2/7 and CD105 were obtained from Abcam (Cambridge, England). The primary antibody against PKG II was from Abgent Biotechnology (San Diego, CA, USA). Antibodies against phospho (p-) and total Erk1/2, EGFR, vascular endothelial growth factor receptor (VEGFR), MKK7, JNK1/2/3, PI3K, Akt, PLCγ1 were obtained from Cell Signaling Technology (Danvers, MA, USA). A terminal deoxynucleotidyl transferased deoxyuridine triphosphate(dUTP) nick-end labelling (TUNEL) In Situ Cell Death Detection Kit was purchased from Roche Diagnostics (Mannheim, Germany), and electrochemiluminescence (ECL) reagents were purchased from Millipore (Billerica, MA, USA).
Construction of constitutively active Type II cyclic guanosine monophosphate-dependent protein kinase (a-PKG II) and adenovirus (Ad) vector
The human PKG II gene was recombined into a pAdeno-MCMV-3Flag-IRES2-EGFP vector at the NheI site, with 3Flag-tags located at the N-terminus, and the construct was named Ad-wt-PKG II (Supplementary Figure 1) . The a-PKG II was generated using a QuikChange site-directed 17, 18 Briefly, when the subcutaneous tumour grew to 5 mm in diameter, the tumour tissue was excised from the mouse and then minced. The minced tissue was used as the new subcutaneous transplant for the next group, and this subcutaneous transplantation was repeated for six generations. The tumour tissue from the sixth-generation nude mice was minced to 1-2 mm 3 and then transplanted inside the seromuscular layer of the greater curvature of the stomachs. For in vivo treatment, Ad-wt-PKG II or Ad-a-PKG II (1 × 10 9 pfu) was administered via intraperitoneal (i.p.) injection on day 0, and the administration was repeated every 4 days. At the end of the experiments, the mice were killed and all tumours were removed and weighed.
Immunohistochemistry Formalin-fixed paraffin-embedded tumour tissue was used for immunohistochemical analysis, as described previously. 19 The immunohistochemical panel comprised the following antibodies targeting the following proteins: proliferating cell nuclear antigen (PCNA) and matrix metalloproteinase 2/7 (MMP-2/7).
Western blotting
Whole-cell lysates were prepared by using a Total Protein Extraction Kit (KeyGEN Bio TECH, Shanghai, China). Equal amounts of protein were separated via 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% nonfat dried milk in Tris-buffered saline containing 0.1% Tween 20 (MilliporeSigma, Billerica, MA, USA), and incubated with specific primary antibodies against PCNA, p-EGFR (Tyr992, 1068, 1173), EGFR, p-Erk1/2 (Thr 202/Tyr 204), Erk1/2, CD105, p-PLCγ1 (Tyr783), PLCγ1, p-MKK7 (Ser271/Thr275), MKK7, p-JNK1/2/3 (Thr183+Tyr185), JNK1/2/3, p-PI3K (Tyr458), PI3K, p-Akt (Thr308), Akt, Flag, or β-actin overnight at 4°C. After washing, horseradish peroxidase-labelled (HRP) secondary antibodies were added for 1 h at 37°C. Detection was performed using ECL.
Terminal deoxynucleotidyl transferased deoxyuridine triphosphate (dUTP) nick-end labelling detection
Formalin-fixed paraffin-embedded tumour tissues were used for TUNEL analysis, according to the manufacturer's instructions. TUNEL-stained slides were evaluated in a double-blind manner by two independent investigators. Images were captured by an Olympus BX45 microscope (Olympus, Tokyo, Japan).
Statistical analysis
All statistical analyses were performed using Graph Pad Prism software (GraphPad Software Inc., La Jolla, CA, USA). The data are expressed as the mean ± standard deviation (SD). Significance was determined with a paired t test or oneway ANOVA with Bonferroni correction, and p < 0.05 was considered significant for all tests.
Results
Expression of Ad-constitutively active Type II cyclic guanosine monophosphate-dependent protein kinase (Ad-a-PKG II) in 293A cells and identification of activity and distribution of PKG II overexpression in vivo
Ad-wt-PKG II and Ad-a-PKG II vectors were constructed successfully and demonstrated to upregulate PKG II expression both in 293A cells and BGC-823 cells ( Figure 1 A-C). Previous data indicated that the inhibitory effect of PKG II on cell proliferation were partially dependent on VASP. 20, 21 We also noted that VASP phosphorylation (at serine 239) was observed in Ad-a-PKG II-infected BGC-823 cell line; however, a similar phenomenon was not detected in cells infected with Ad-wt-PKG II ( Figure 1C ). These results indicated that a-PKG II effectively promoted phosphorylation of VASP. Following i.p. or intravenous (i.v.) injection of Ad-a-PKG II into nude BALB/c mice, PKG II expression was detected in the stomach, the small intestine, and the liver of the mice. Following i.p. injection of adenovirus, PKG II was detected on day 2, with levels peaking on day 4 followed by gradual downexpression. PKG II expression was obviously decreased after 8 days ( Figure 1D ). Conversely, following i.v. injection of adenovirus, PKG II was highly expressed in the liver with lower levels in the stomach and small intestine on day 2, and remained detectable in the liver after 10 days ( Figure 1D ). A similar phenomenon was also obtained in the Ad-wt-PKG II infection group (data not shown). However, there were not obvious changes of exogenous of PKG II in the heart after i.v. injection of adenovirus for 2-12 days (Supplementary Figure 2) . The above results indicated that a-PKG II effectively promoted phosphorylation of VASP and resulted in extensive expression of PKG II/a-PKGII in the stomach, small intestine, and liver with i.p. injection. Therefore, i.p. injection was used in subsequent experiments in tumour-bearing mice. Figure 2A) . Notably, survival was also significantly prolonged in Ad-a-PKG II-infected tumourbearing mice ( Figure 2B ). To confirm the inhibitory effect dependent on exogenous PKG II transfection, the Flag and PKG II were both detected in tumours to differentiate the exogenous or endogenous expression, the results showed that the tumour tissues expressed low-level endogenous PKG II (Supplementary Figure 3) .
The proliferative potential of the transplantation tumours was determined by detecting the expression of the proliferation marker PCNA. 22 PCNA expression was downregulated in Ad-a-PKG II group compared with Ad-GFP-infected mice. There was no obvious difference between Ad-a-PKG II and AG1478 group, as shown by western blotting, while PCNA levels were also slightly decreased by Ad-wt-PKG II ( Figure 2C ). Similar results were obtained with immunohistochemistry ( Figure 2D ). Overall, these results showed that infection with Ad-a-PKG II effectively inhibited development/growth of orthotopic transplantation tumour.
Infection of Ad-a-PKG II induced apoptosis of cancer cells and inhibited metastasis and angiogenesis
TUNEL analysis and western blotting were used to explore the potential mechanisms responsible for the antitumour effects of a-PKG II in vivo.
As Figure 3A showed, Ad-a-PKG II infection significantly induced apoptosis compared with the Ad-GFP and Ad-wt-PKG II groups, with AG1478 as the positive control. The effects on expression of Bax and Bcl-2, and cleavage of caspase-3 were also analysed. The results showed that Ad-a-PKG II infection inhibited Bcl-2 expression but promoted expression of Bax, and contributed to cleavage of caspase-3 ( Figure 3B ).
The expression of tumour-metastasis-associated proteins MMP-2/7 and E-cadherin was also detected. The results showed that MMP-2/7 expression was significantly downregulated by infection with Ad-a-PKG II compared with Ad-wt-PKG II or Ad-GFP ( Figure 3C) , while E-cadherin expression was upregulated in the Ad-a-PKG II group, and the similar phenomena were also found in the positive control group (AG1478). These results were confirmed by immunohistochemistry ( Figure 3D ).
a-PKG II infection also inhibited phosphorylation of VEGFR and expression of CD105 (endoglin), a marker of neovascularization, compared with the Ad-GFP and Ad-wt-PKG II infected groups, with no obvious differences between the latter two groups. And there were similar results found in the positive control group (AG1478) ( Figure 3E ). These results indicated that a-PKG II might inhibit angiogenesis. Overall, Ad-a-PKG II infection obviously induced cancer cell apoptosis, and inhibited metastasis and angiogenesis.
a-PKG II infection inhibited epidermal growth factor receptor-dependent growth of transplanted orthotopic tumour via abrogation of epidermal growth factor/epidermal growth factor receptor signalling cascades
EGFR has been demonstrated to have extensive roles in tissue homeostasis and cancer biology, with notable involvement in cancer development through ligand binding, signal transduction, and membrane trafficking. 23, 24 Next, it was determined whether Ad-a-PKG II infection inhibited gastric transplanted orthotopic tumour via abrogation of EGF/EGFR signalling cascades, and western blotting results showed that the Ad-a-PKG II infection significantly inhibited phosphorylation on Tyr1068, 1173, and 992 of EGFR ( Figure 4 ). Since these tyrosine sites were linked to downstream signals including MAPK, PI3K/ Akt, and PLCγ1, respectively, the activation of the related signalling cascades were also analysed. The results showed that Ad-a-PKG II infection inhibited phosphorylation of Erk1/2 on Thr202/ Tyr204, MKK7 on Ser271/Tyr275, JNK1/2/3 on Thr183/Tyr185, PI3K on Tyr458, Akt on Thr308, and PLCγ1 on Tyr783, similar to the results in the positive control group (AG1478) (Figure 4 Representative photomicrographs of immunohistochemical detection of MMP-2/7 in tumour tissues. MMP-2/7 was primarily detected in the cytoplasm. Brown, MMP-2/7 staining; blue, nuclear staining. (E) a-PKG II inhibited CD105 expression and phosphorylation of VEGFR. β-actin was served as the loading control and Flag was examined to determine PKG II expression. L-CD105 and S-CD105 refer to long and short isoforms of CD105, respectively. All the data were obtained from eight mice ( * p < 0.05, compared with Ad-GFP group).
PKG II, type II cyclic guanosine monophosphate-dependent protein kinase; Ad-a, adenovirus active; Ad-wt, adenovirus wild-type; i.p., intraperitoneal; TUNEL, terminal deoxynucleotidyl transferased dUTP nick-end labelling; VEGFR, vascular endothelial growth factor receptor; GFP, green fluorescent protein; MMP, matrix metalloproteinase; CD105, endoglin; L-CD105, long isoform of endoglin; S-CD105, short isoform of endoglin; AG1478, tyrphostin AG1478 . It will be significant to find a novel EGFR inhibitor for the therapy of the cancers.
PKGs, including PKG I and PKG II isoforms, have aroused recent interest, and have been shown to exert important effects on tumour proliferation and angiogenesis by inhibiting β-catenin/T-cell factor and SOX9 signalling. 6, 26 Additionally, published data have also indicated that PKG activation can inhibit β-catenin shuttling, reduce β-catenin levels, or suppress its transcriptional activity. [27] [28] [29] PKG I also induces apoptosis and inhibits tumour proliferation and metastasis, and has been identified as a tumour suppressor. 30 Conversely, PKG II is a membraneanchored enzyme implicated in intestinal secretion, hypertrophic differentiation of chondrocytes, and endochondral ossification. 10, 31 Recent data have indicated that human glioma cells transfected with a PKG II expression vector showed an obvious reduced colony formation and cell proliferation, and an accumulation of cells in the G1 phase, in a cGMP-dependent manner. 32 We also previously demonstrated that PKG II inhibited tumourigenesis and metastasis, by inhibition of EGFR activation and downstream signalling cascades in vitro. 14, 33, 34 These results suggested that PKG II may represent a novel target for biological therapy of EGFR-dependent cancers in vitro. However, it remains unclear whether PKG II plays an inhibitory role in tumour development in vivo. Moreover, PKGs need cGMP or cGMP analogues for the activation to exert biological activities. In vivo, cGMP or cGMP analogues will cause multiple effects besides activating PKG II. So, in this paper, a constitutively a-PKG II was constructed and used to investigate the inhibitory effect of PKG II on cancer in vivo.
PKG II, as a protein kinase, is activated by cGMP or cGMP analogues and then is shown to have an inhibitory effect on tumour growth. 13, 35, 36 In fact, PKG II is known to be autophosphorylated in vitro at multiple sites, including Ser 110, 114, and 445 located close to the pseudosubstrate region. However, Ser126 phosphorylation had a major effect on the activity of PKG II and autophosphorylation at the other sites had only minor effects on the kinetic parameters of PKG II. 1 Research data showed that Ser126 of PKG II mutation into glutamate mimics the phosphorylation process. 1, 37 So, we constructed a PKG II mutant in which Ser126 was replaced with glutamate. And the mutant effectively promoted VASP phosphorylation independent of cGMP or cGMP analogues. 
